Cat. No.: HY-15230

Geldanamycin

41 Cited Publications

Customer Review

Based on 41 publication(s) in Google Scholar

Geldanamycin is a Hsp90 inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria. Geldanamycin has anti-influenza virus H5N1 activities.

For research use only. We do not sell to patients.

Purity: 99.58%
CAS No.: 30562-34-6
Formula: C₂₉H₄₀N₂O₉
Molecular Weight:560.64

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Geldanamycin Chemical Structure

CAS No.: 30562-34-6

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (41)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Geldanamycin is a Hsp90 inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria. Geldanamycin has anti-influenza virus H5N1 activities.

IC₅₀ & Target^[4]

HSP90

1.2 μM (Kd)

All HSP Isoforms :

All Antibiotic Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.07 μM Compound: 1	Antiproliferative activity against human A2780 assessed as reduction in cell viability measured after 96 hrs by MTT assay Antiproliferative activity against human A2780 assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 27476419]
A-375	IC₅₀	0.06 μM Compound: 1	Antiproliferative activity against human A375 assessed as reduction in cell viability measured after 96 hrs by MTT assay Antiproliferative activity against human A375 assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 27476419]
A-431	IC₅₀	0.2 μM Compound: geldanamycin	Antiproliferative activity against human A431 cells after 72 hrs Antiproliferative activity against human A431 cells after 72 hrs	[PMID: 20655237]
A-431	IC₅₀	40 nM Compound: 1, GA	Cytotoxicity against human A431 cells after 72 hrs by MTT assay Cytotoxicity against human A431 cells after 72 hrs by MTT assay	[PMID: 25277067]
A549	IC₅₀	0.1 μM Compound: GA	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 29172085]
A549	IC₅₀	0.109 μM Compound: Geldanamycin	Anticancer activity against human A549 cells measured after 72 hrs by SRB assay Anticancer activity against human A549 cells measured after 72 hrs by SRB assay	[PMID: 27283788]
A549	IC₅₀	0.15 μM Compound: geldanamycin	Cytotoxicity against human A549 cells after 2 days by AlamarBlue assay Cytotoxicity against human A549 cells after 2 days by AlamarBlue assay	[PMID: 23947794]
A549	IC₅₀	0.99 μM Compound: GDM	Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
A549	IC₅₀	97 nM Compound: 1, GA	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 25277067]
BGC-823	IC₅₀	0.11 μM Compound: 1	Antiproliferative activity against human BGC823 assessed as reduction in cell viability measured after 96 hrs by MTT assay Antiproliferative activity against human BGC823 assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 27476419]
BGC-823	IC₅₀	40 nM Compound: 1, GA	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 25277067]
CAKI-1	IC₅₀	0.056 μM Compound: Geldanamycin	Anticancer activity against human Caki1 cells measured after 72 hrs by SRB assay Anticancer activity against human Caki1 cells measured after 72 hrs by SRB assay	[PMID: 27283788]
CNE2Z	IC₅₀	0.31 μM Compound: GM	Antiproliferative activity against human CNE2Z cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human CNE2Z cells assessed as cell growth inhibition by MTT assay	[PMID: 32527461]
HCT-116	EC₅₀	0.03 μM Compound: 1	Antiproliferative activity against human HCT116 cells measured on day 4 by Cell titer-glo assay Antiproliferative activity against human HCT116 cells measured on day 4 by Cell titer-glo assay	[PMID: 21420297]
HCT-116	EC₅₀	0.03 μM Compound: 1	Antiproliferative activity against human HCT116 cells by luminescence assay Antiproliferative activity against human HCT116 cells by luminescence assay	[PMID: 21605975]
HCT-116	IC₅₀	0.1 μM Compound: 1	Antiproliferative activity against human HCT116 assessed as reduction in cell viability measured after 96 hrs by MTT assay Antiproliferative activity against human HCT116 assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 27476419]
HCT-116	IC₅₀	0.15 μM Compound: Geldanamycin	Anticancer activity against human HCT116 cells measured after 72 hrs by SRB assay Anticancer activity against human HCT116 cells measured after 72 hrs by SRB assay	[PMID: 27283788]
HeLa	IC₅₀	>5 μM Compound: Geldanamycin	Cytotoxicity against human HeLa cells at 72 hrs by MTS assay Cytotoxicity against human HeLa cells at 72 hrs by MTS assay	[PMID: 22162786]
HeLa	IC₅₀	0.06 μM Compound: GA	Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay	[PMID: 27266997]
HeLa	IC₅₀	798 nM Compound: 1, GA	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 25277067]
HepG2	IC₅₀	0.3 μM Compound: GDM	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 23656556]
HepG2	IC₅₀	1.74 μM Compound: GM	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by MTT assay	[PMID: 32527461]
HepG2	IC₅₀	40 nM Compound: 1, GA	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 25277067]
Huh-7	EC₅₀	0.25 nM Compound: Geldanamycin	Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days by qRT-PCR analysis Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days by qRT-PCR analysis	[PMID: 18936191]
Huh-7	EC₅₀	1.2 nM Compound: Geldanamycin	Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis	[PMID: 18936191]
HUVEC	IC₅₀	19 nM Compound: 1, GA	Cytotoxicity against HUVEC cells after 72 hrs by MTT assay Cytotoxicity against HUVEC cells after 72 hrs by MTT assay	[PMID: 25277067]
L02	IC₅₀	141 nM Compound: 1, GA	Cytotoxicity against human HL7702 cells after 72 hrs by MTT assay Cytotoxicity against human HL7702 cells after 72 hrs by MTT assay	[PMID: 25277067]
L6	IC₅₀	6 μM Compound: GA	Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay	[PMID: 24580531]
LNCaP	IC₅₀	0.43 μM Compound: GA	Cytotoxicity against human LNCAP cells after 72 hrs by MTT assay Cytotoxicity against human LNCAP cells after 72 hrs by MTT assay	[PMID: 25105924]
LS174T	IC₅₀	0.45 μM Compound: GA	Cytotoxicity against human LS174T cells by MTS assay Cytotoxicity against human LS174T cells by MTS assay	[PMID: 17034135]
MCF7	GI₅₀	35.6 μM Compound: geldanamycin	Growth inhibition of human MCF7 cells after days by SRB assay Growth inhibition of human MCF7 cells after days by SRB assay	[PMID: 17869098]
MCF7	IC₅₀	0.04 μM Compound: GDA	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS/PMS assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS/PMS assay	[PMID: 25075762]
MCF7	IC₅₀	0.0427 μM Compound: 1, GDA	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS/PMS assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS/PMS assay	[PMID: 25756299]
MCF7	IC₅₀	0.053 μM Compound: Geldanamycin	Cytotoxicity against human MCF7 cells at 72 hrs by MTS assay Cytotoxicity against human MCF7 cells at 72 hrs by MTS assay	[PMID: 22162786]
MCF7	IC₅₀	0.11 μM Compound: 1	Antiproliferative activity against human MCF7 assessed as reduction in cell viability measured after 96 hrs by MTT assay Antiproliferative activity against human MCF7 assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 27476419]
MCF7	IC₅₀	9.6 μM Compound: Geldanamycin	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 19560353]
MCF7	IC₅₀	9.8 nM Compound: 5, GDA	Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 72 hrs Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 72 hrs	[PMID: 23648180]
MDA-MB-231	IC₅₀	0.03 μM Compound: GA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 27266997]
MDA-MB-231	IC₅₀	0.05 μM Compound: 1, GA	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 25277067]
MDA-MB-231	IC₅₀	0.05 μM Compound: GA	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 25105924]
MDA-MB-231	IC₅₀	0.06 μM Compound: GA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 29172085]
MDA-MB-231	IC₅₀	0.11 μM Compound: Geldanamycin	Anticancer activity against human MDA-MB-231 cells measured after 72 hrs by SRB assay Anticancer activity against human MDA-MB-231 cells measured after 72 hrs by SRB assay	[PMID: 27283788]
MDA-MB-231	IC₅₀	0.62 μM Compound: GM	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTT assay	[PMID: 32527461]
NCI-H1975	GI₅₀	0.56 μM Compound: 1; GA	Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells after 1 to 3 days by MTS assay Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells after 1 to 3 days by MTS assay	[PMID: 27783977]
NCI-H1975	GI₅₀	0.56 μM Compound: GA	Antiproliferative activity against human NCI-H1975 cells after 72 hrs by Cell Titer 96 Aqueous One Solution cell proliferation assay Antiproliferative activity against human NCI-H1975 cells after 72 hrs by Cell Titer 96 Aqueous One Solution cell proliferation assay	[PMID: 29202402]
P19	IC₅₀	0.1 μM Compound: 1	Cytotoxicity against mouse P19 cells after 18 hrs Cytotoxicity against mouse P19 cells after 18 hrs	[PMID: 17442565]
PC-3	IC₅₀	0.73 μM Compound: GDM	Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
RPMI-8226	GI₅₀	0.003 μM Compound: Geldanamycin	Growth inhibition of human RPMI8226 cells after 72 hrs by MTS/PMS assay Growth inhibition of human RPMI8226 cells after 72 hrs by MTS/PMS assay	[PMID: 29057043]
Sf9	IC₅₀	74 nM Compound: Geldanamycin	Displacement of GM-BODIPY from human full length HSP90 alpha expressed in baculovirus-infected Sf9 cells after 16 hrs by fluorescence polarization assay Displacement of GM-BODIPY from human full length HSP90 alpha expressed in baculovirus-infected Sf9 cells after 16 hrs by fluorescence polarization assay	[PMID: 24751441]
SK-BR-3	GI₅₀	0.43 μM Compound: 1; GA	Antiproliferative activity against Her2-overexpressing human SKBR3 cells after 1 to 3 days by MTS assay Antiproliferative activity against Her2-overexpressing human SKBR3 cells after 1 to 3 days by MTS assay	[PMID: 27783977]
SK-BR-3	IC₅₀	0.87 μM Compound: GDM	Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
SK-BR-3	IC₅₀	41 nM Compound: GDM	Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-glo assay Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-glo assay	[PMID: 19405528]
SK-BR-3	IC₅₀	8.5 nM Compound: 5, GDA	Antiproliferative activity against estrogen receptor deficient human SKBR3 cells after 72 hrs Antiproliferative activity against estrogen receptor deficient human SKBR3 cells after 72 hrs	[PMID: 23648180]
SK-OV-3	IC₅₀	0.94 μM Compound: GDM	Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
SMMC-7721	IC₅₀	0.11 μM Compound: GM	Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition by MTT assay	[PMID: 32527461]
SNU-638	IC₅₀	0.03 μM Compound: Geldanamycin	Anticancer activity against human SNU638 cells measured after 72 hrs by SRB assay Anticancer activity against human SNU638 cells measured after 72 hrs by SRB assay	[PMID: 27283788]
SW1990	IC₅₀	0.29 μM Compound: 1	Antiproliferative activity against human SW1990 assessed as reduction in cell viability measured after 96 hrs by MTT assay Antiproliferative activity against human SW1990 assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 27476419]
SW480	IC₅₀	0.51 μM Compound: GM	Antiproliferative activity against human SW480 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human SW480 cells assessed as cell growth inhibition by MTT assay	[PMID: 32527461]
SW480	IC₅₀	310 nM Compound: 1, GA	Cytotoxicity against human SW480 cells after 72 hrs by MTT assay Cytotoxicity against human SW480 cells after 72 hrs by MTT assay	[PMID: 25277067]
U-87MG ATCC	EC₅₀	0.089 μM Compound: 1	Antiproliferative activity against human U87 cells by luminescence assay Antiproliferative activity against human U87 cells by luminescence assay	[PMID: 21605975]
U-87MG ATCC	IC₅₀	0.81 μM Compound: GDM	Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]

In Vitro

Geldanamycin significantly delays and reduces viperin expression, indicating that IRF3 is involved in viperin induction in RAW264.7 cells^[1].
Geldanamycin, a benzoquinone ansamycin, protected against neuronal injury induced by oxygen-glucose deprivation (OGD)/zVAD treatment in cultured primary neurons. More importantly, Geldanamycin decreases RIP1 protein level in a time and concentration-dependent manner. Geldanamycin also decreases the Hsp90 protein level, which causes instability of RIP1 protein, resulting in decreased RIP1 protein level but not RIP1 mRNA level after Geldanamycin treatment^[2].
Geldanamycin is identified as the first natural product inhibitor of Hsp90 that binds to the N-terminal ATPase domain of Hsp90 to inhibit its chaperone function, and significantly induces tumor cell death via an apoptotic mechanism^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 30562-34-6
Appearance Solid
Molecular Weight 560.64
Formula C₂₉H₄₀N₂O₉
Color Light yellow to orange
SMILES

O=C(C1=C2OC)C(NC(/C(C)=C/C=C\[C@H](OC)[C@@H](OC(N)=O)/C(C)=C/[C@H](C)[C@H]([C@@H](OC)C[C@@H](C1)C)O)=O)=CC2=O
Structure Classification
- Quinones
- Benzene Quinones
Initial Source
- Microorganisms
Streptomyces hygroscopicus
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (41)

All WB

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

A Cullin 5-based complex serves as an essential modulator of ORF9b stability in SARS-CoV-2 replication. [Abstract]

2024 Jun 28;9(1):159. PMID: 38937432
Nat Commun

Chloroplast precursor protein preClpD overaccumulation triggers multilevel reprogramming of gene expression and a heat shock-like response. [Abstract]

2025 Apr 22;16(1):3777. PMID: 40263324
Nat Commun

Small molecule in situ resin capture provides a compound first approach to natural product discovery. [Abstract]

2024 Jun 19;15(1):5230. PMID: 38898025
Nat Commun

PIF7 is a master regulator of thermomorphogenesis in shade. [Abstract]

2022 Aug 29;13(1):4942. PMID: 36038577
Nat Commun

An infection-induced RhoB-Beclin 1-Hsp90 complex enhances clearance of uropathogenic Escherichia coli. [Abstract]

2021 May 10;12(1):2587. PMID: 33972537
Acta Pharm Sin B

2026 Feb 2026 Feb 26.
Autophagy

HSPA8 regulates anti-bacterial autophagy through liquid-liquid phase separation. [Abstract]

2023 Oct;19(10):2702-2718. PMID: 37312409
Adv Sci (Weinh)

Pyroptosis-Inducing Engineered Microparticles for Cancer Immunotherapy. [Abstract]

2026 Mar 18:e74886. PMID: 41848091
Nucleic Acids Res

Necdin regulates BMAL1 stability and circadian clock through SGT1-HSP90 chaperone machinery. [Abstract]

2020 Aug 20;48(14):7944-7957. PMID: 32667666
Adv Healthc Mater

Peptomer Linkers Enable Kinetic Control over Co-Delivery of Multiple Chemotherapeutics. [Abstract]

2025 Dec 30:e04277. PMID: 41472401
J Pharm Anal

2026 Mar 11.
Acta Pharmacol Sin

Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity. [Abstract]

2022 Apr;43(4):1046-1058. PMID: 34326484
Phytomedicine

Parthenolide inhibits Hsp90α ATPase activity and overcomes acquired BRAF-inhibitor resistance in cutaneous melanoma. [Abstract]

2025 Oct:146:157151. PMID: 40815947
New Phytol

HSP90s are required for hypocotyl elongation during skotomorphogenesis and thermomorphogenesis via the COP1-ELF3-PIF4 pathway in Arabidopsis. [Abstract]

2023 Aug;239(4):1253-1265. PMID: 36707919
Cell Syst

A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. [Abstract]

2018 Apr 25;6(4):424-443.e7. PMID: 29655704
Cell Prolif

Targeting Hsp90α to inhibit HMGB1-mediated renal inflammation and fibrosis. [Abstract]

2024 Nov 20:e13774. PMID: 39566909
Liver Int

Human poliovirus receptor contributes to biliary atresia pathogenesis by exacerbating natural-killer-cell-mediated bile duct injury. [Abstract]

2022 Dec;42(12):2724-2742. PMID: 36251580
Liver Int

Inhibition of HSPA8 by rifampicin contributes to ferroptosis via enhancing autophagy. [Abstract]

2022 Dec;42(12):2889-2899. PMID: 36254713
Nutrients

Dietary Flavone Baicalein Combinate with Genipin Attenuates Inflammation Stimulated by Lipopolysaccharide in RAW264.7 Cells or Pseudomonas aeruginosa in Mice via Regulating the Expression and Phosphorylation of AKT. [Abstract]

2021 Dec 14;13(12):4462. PMID: 34960014
Int J Mol Sci

HER2-Driven Breast Cancer: Role of the Chaperonin HSP90 in Modulating Response to Trastuzumab-Based Therapeutic Combinations. [Abstract]

2025 Jul 9;26(14):6593. PMID: 40724844
Eur J Pharmacol

GART promotes multiple myeloma malignancy via tumor stemness mediated by activating the HSP90α/CDK6/β-catenin axis. [Abstract]

2025 Apr 2:996:177584. PMID: 40185325
Int Immunopharmacol

Inhibiting HMGB1/AGER/NF-κB pathway prevents pro-inflammatory microglia polarization and protect photoreceptors in retinitis pigmentosa. [Abstract]

2025 Feb 3:149:114192. PMID: 39904032
Antimicrob Agents Chemother

Multiple Genes of Candida albicans Influencing Echinocandin Susceptibility in Caspofungin-Adapted Mutants. [Abstract]

2022 Dec 20;66(12):e0097722. PMID: 36354349
Water Biol Secur

2025 Apr 8.
FEBS J

Ligand-dependent protein interactions of the juvenile hormone receptor captured in real time. [Abstract]

2023 Jun;290(11):2881-2894. PMID: 36609881
iScience

Deficiency in Prader-Willi syndrome gene necdin leads to attenuated cardiac contractility. [Abstract]

2024 May 14;27(6):109974. PMID: 38832028
iScience

QHRD106 ameliorates ischemic stroke injury as a long-acting tissue kallikrein preparation. [Abstract]

2023 Jul 3;26(7):107268. PMID: 37496671
J Virol

Heat shock protein 90 chaperone activity is required for hepatitis A virus replication. [Abstract]

2025 Jun 5:e0050225. PMID: 40470959
J Cell Sci

Mitochondrial respiration promotes Cdc37-dependent stability of the Cdk1 homolog Cdc28. [Abstract]

2023 Jan 1;136(1):jcs260279. PMID: 36594787
Exp Cell Res

The involvement of endogenous melatonin in LPS-induced M1-like macrophages and its underlying synthesis mechanism regulated by IRF3. [Abstract]

2024 Oct 29:114314. PMID: 39481795
Chem Asian J

Selective Protein Degradation through Tetrazine Ligation of Genetically Incorporated Unnatural Amino Acids. [Abstract]

2024 Sep 2:e202400824. PMID: 39221720
Mol Immunol

Comprehensive analysis of lncRNA-mRNA regulatory network in BmNPV infected cells treated with Hsp90 inhibitor. [Abstract]

2020 Nov;127:230-237. PMID: 33022580
J Cell Biochem

Geldanamycin induces apoptosis and inhibits inflammation in fibroblast-like synoviocytes isolated from rheumatoid arthritis patients. [Abstract]

2019 Sep;120(9):16254-16263. PMID: 31087698

Geldanamycin purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2019 Sep;120(9):16254-16263. [Abstract]

Bcl2, Bax, and β-actin protein expression is analyzed by Western blot with the treatment of Geldanamycin.

Geldanamycin purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2019 Sep;120(9):16254-16263. [Abstract]

Caspase 3, caspase 9, cleaved caspase 3, cleaved caspase 9, and β-actin protein expression analyzed by Western blot with the treatment of Geldanamycin.
J Cell Biochem

Chemical inhibition of HSP90 inhibits TNF-α mediated proliferation and induces apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes. [Abstract]

2019 Feb;120(2):2547-2553. PMID: 30304567

Geldanamycin purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2019 Feb;120(2):2547-2553. [Abstract]

Geldanamycin (GA) attenuatea TNF-α-mediated activation of MAPK and NF-κB signaling pathways.
bioRxiv

Tau-induced mitochondrial reverse electron transport drives neurodegeneration. [Abstract]

2026 Apr 7:2026.04.04.716514. PMID: 41993559
bioRxiv

2025 Oct 2.
Keimyung University

2025.
bioRxiv

2023 Sep 8.
Research Square Preprint

2023 May 22.
Research Square Preprint

2022 Jul.
Research Square Preprint

2022 May.

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (44.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7837 mL

8.9184 mL

17.8368 mL

5 mM

0.3567 mL

1.7837 mL

3.5674 mL

10 mM

0.1784 mL

0.8918 mL

1.7837 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (4.46 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (4.46 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Tang HB, et al. Viperin inhibits rabies virus replication via reduced cholesterol and sphingomyelin and is regulated upstream by TLR4. Sci Rep. 2016 Jul 26;6:30529 [Content Brief]

[2]. Chen WW, et al. RIP1 mediates the protection of Geldanamycin on neuronal injury induced by oxygen-glucosedeprivation combined with zVAD in primary cortical neurons. J Neurochem. 2012 Jan;120(1):70-7. [Content Brief]

[3]. Lin Z, et al. 17-ABAG, a novel Geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition. Int J Mol Med. 2015 Aug;36(2):424-32. [Content Brief]

[4]. Roe SM, et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem. 1999 Jan 28;42(2):260-6. [Content Brief]

[5]. Wang C, et al. Geldanamycin Reduces Acute Respiratory Distress Syndrome and Promotes the Survival of Mice Infected with the Highly Virulent H5N1 Influenza Virus. Front Cell Infect Microbiol. 2017 Jun 15;7:267. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7837 mL	8.9184 mL	17.8368 mL	44.5919 mL
	5 mM	0.3567 mL	1.7837 mL	3.5674 mL	8.9184 mL
	10 mM	0.1784 mL	0.8918 mL	1.7837 mL	4.4592 mL
	15 mM	0.1189 mL	0.5946 mL	1.1891 mL	2.9728 mL
	20 mM	0.0892 mL	0.4459 mL	0.8918 mL	2.2296 mL
	25 mM	0.0713 mL	0.3567 mL	0.7135 mL	1.7837 mL
	30 mM	0.0595 mL	0.2973 mL	0.5946 mL	1.4864 mL
	40 mM	0.0446 mL	0.2230 mL	0.4459 mL	1.1148 mL

Keywords

Geldanamycin

41 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Geldanamycin

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Antibacterial Compound Library

Endoplasmic Reticulum Stress Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Antibiotics Library

Microbial Metabolite Library

Anti-Cancer Natural Product Library

Anti-Prostate Cancer Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Extracellular Vesicles (EVs) Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

Covalent Screening Library Plus

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Quinones Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Bacteria-Sourced Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Geldanamycin

All HSP Isoforms

All Antibiotic Isoforms

Biological Activity

Chemical Information

Publications (41)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Geldanamycin Related Classifications

Cat. No.: HY-15230